Comparing advanced treatments for ulcerative colitis after anti-TNF therapy
Treatments studied
Part of Digestive system clinical trials.
This trial compares three types of medications (vedolizumab, ustekinumab, and JAK inhibitors) in people with ulcerative colitis who have already tried an anti-TNF drug but still have active disease. The goal is to see which treatment works best as a second option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of ulcerative colitis (UC).
- You are 18 years or older and able to give informed consent.
- Your UC is currently active (symptoms like diarrhea, urgency, or blood in stool).
- You have tried at least one anti-TNF drug (like infliximab, adalimumab, or golimumab) for UC.
- You are starting a new treatment with vedolizumab, ustekinumab, or a JAK inhibitor (tofacitinib, upadacitinib, filgotinib) as your second advanced therapy.
- You have not taken vedolizumab, ustekinumab, or any JAK inhibitor for UC before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
This trial tests three different types of biologic medications to find which works best as a first treatment for moderate-to-severe ulcerative colitis.
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
Hear when a new Ulcerative Colitis (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.